Location out of bounds
Radial
Radial

Newsroom

Resources for journalists

All Press Releases
Versiti Logo

BloodCenter of Wisconsin launches breakthrough FDA approved leukemia test

Milwaukee – August 29, 2017

BloodCenter of Wisconsin’s Diagnostic Laboratories, part of Versiti, is the first to offer testing using Abbott Laboratories’ RealTime IDH2 assay that identifies specific gene mutations in patients with acute myeloid leukemia (AML). BloodCenter’s breakthrough offering, which follows Abbott’s recent approval from the U.S. Food and Drug Administration, helps to deliver new and more effective treatments to patients with relapsed and refractory AML.

BloodCenter’s test, IDH2 Abbott RealTime PCR, is more sensitive to detecting the IDH2 genetic mutation found in patients’ blood and bone marrow samples. The method detects single nucleotide variants (SNVs) coding nine IDH2 R140 and R172 mutations in patients’ DNA. With a five-day turnaround time, this test helps identify AML patients that could benefit from new treatments, including the recently FDA approved drug called IDHIFA®.

According to the National Cancer Institute, more than 21,000 people will be diagnosed with AML this year and more than 10,000 patients will die due to the disease. Between 8 percent and 19 percent of AML patients have IDH2 mutations.

"This new test is an exciting addition to BloodCenter’s molecular oncology diagnostics portfolio. Through our collaboration with Abbott, we can continue to help provide better treatment options and outcomes for AML patients,” said Dr. Matthew Anderson, M.D., Ph.D., VP and medical director of the Diagnostic Laboratories at BloodCenter of Wisconsin. “This test will help physicians to provide more customized treatment for patients, and is another example of how BloodCenter is advancing precision medicine in our areas of expertise."

###

Contact Us

Fay Spano

Director, Public Relations and Corporate Communications
Email (414) 937-6124

Other Press Releases

Bears

Chicago Bears and Heartland Blood Centers Launch “Type C Blood” High School Program

May 7, 2018

Heartland Blood Centers and the Chicago Bears announced the kickoff of the “Type C Blood” High School Program that encourages high schools to host blood drives in their community.

Read More
All of Us

Wisconsin researchers join NIH in launching the All of Us Research Program to advance precision medi

May 1, 2018

BloodCenter of Wisconsin takes part in historic research effort

Read More
Brian Bautista

Versiti names new EVP & Chief Operating Officer

April 17, 2018

Versiti has named Brian Bautista Executive Vice President and Chief Operating Officer.

Read More
ic-arrow-right
x

This website uses cookies to ensure you get the best experience on our website. Learn more